Provided by Tiger Trade Technology Pte. Ltd.

Therapeutics

4.72
-0.1900-3.87%
Post-market: 4.720.00000.00%19:57 EDT
Volume:569.05K
Turnover:2.69M
Market Cap:147.69M
PE:-1.14
High:4.88
Open:4.85
Low:4.68
Close:4.91
52wk High:50.40
52wk Low:4.54
Shares:31.29M
Float Shares:18.39M
Volume Ratio:0.78
T/O Rate:3.09%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.1300
EPS(LYR):-2.8503
ROE:-59.21%
ROA:-37.36%
PB:0.67
PE(LYR):-1.66

Loading ...

Beam Therapeutics’ BEAM-302 shows efficacy in Phase 1/2 AATD trial

TIPRANKS
·
Sep 08

Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026

GlobeNewswire
·
Sep 08

Ceryvyn Therapeutics Plans Issue of 3 Million Long-Dated Options

TIPRANKS
·
Sep 08

Prescient Therapeutics Extends Share Purchase Plan Closing Date

MT Newswires Live
·
Sep 08

Alterity Therapeutics Seeks ASX Quotation for 8.4 Million New Shares

TIPRANKS
·
Sep 08

Prescient Therapeutics Extends Securities Purchase Plan Deadline

TIPRANKS
·
Sep 08

Crispr Therapeutics Maintained at Buy as Lp(a) Program Prospects Support Unchanged $88 Price Target

TIPRANKS
·
Sep 07

Genfleet Therapeutics (Shanghai), Inc. Class H (2595) Receives a Buy from Guotai Haitong

TIPRANKS
·
Sep 07

IMPACT Therapeutics Gains Access to Mainland Investors via Stock Connect

TIPRANKS
·
Sep 07

TenNor Therapeutics Advances First-in-Class Prosthetic Joint Infection Drug After Positive Phase IIa Data

TIPRANKS
·
Sep 07

Percheron Therapeutics to List 300 Million New Shares on ASX

TIPRANKS
·
Sep 07

Percheron Therapeutics Sets Hybrid Annual General Meeting for October 2026

TIPRANKS
·
Sep 07

Defence Therapeutics Details First Settlement Under Sorbie Sharing Agreement

TIPRANKS
·
Sep 05

Rein Therapeutics Highlights LTI-03 Progress in IPF

TIPRANKS
·
Sep 05

Spyre Therapeutics Announces Grants of Inducement Awards

GlobeNewswire
·
Sep 05

Allogene Therapeutics management to meet with Piper Sandler

TIPRANKS
·
Sep 05

XORTX Therapeutics Finalizes TSXV Delisting and Re-engages IR Agency in US$2.5 Million Nasdaq-Focused Campaign

TIPRANKS
·
Sep 04

EXACT Therapeutics details shareholder guidance ahead Oslo delisting

TIPRANKS
·
Sep 04

Citigroup Initiates Dianthus Therapeutics at Buy With $156 Price Target

MT Newswires Live
·
Sep 04

Chimeric Therapeutics Seeks ASX Quotation for 14.8 Million New Shares

TIPRANKS
·
Sep 04